Clinical Trial Update: A Phase III Study to Assess the Efficacy and Safety of GV1001-Gem/Cap vs Gem/Cap in Pancreatic Cancer Patients [Phase 3]

View source ↗

Summary

A Phase III trial evaluating the efficacy and safety of the GV1001-Gem/Cap regimen versus Gemcitabine/Capecitabine in pancreatic cancer, with the study status l…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• GV1001-Gem/Cap (GV1001-Gemcitabine/Capecitabine)
• Gemcitabine/Capecitabine (Gemcitabine/Capecitabine)

Snippet

Sponsor: Samsung Pharmaceutical Co., Ltd. | Conditions: Pancreatic Cancer | Phase 3 | Status: UNKNOWN